Sponsored by:

Molecular Imaging

First patients treated in RYZ401 radiopharmaceutical trial
By AuntMinnie.com staff writers
RYZ401 is an investigational actinium-225 (AC-225)-based radiopharmaceutical targeting somatostatin receptors in neuroendocrine tumors.
April 8, 2026
Atom Molecule
New method decouples Alzheimer's disease pathology at PET
By Liz Carey
AI-derived scoring tool shows independent associations, according to researchers.
April 7, 2026
Adversarial decomposition learning (ADL) enables intuitive, longitudinal visualization of disease progression and treatment response, supporting clinician–artificial intelligence collaboration. (A) Images in a 48-year-old female patient who presented with mild cognitive impairment. The ADL probability maps highlighted occipital-temporal amyloid β (Aβ) spread and focal left-temporal tau pathologic abnormalities. An area of increased occipital AV45 uptake is shown (arrowhead). (B) Images in a 51-year-old male who presented with memory decline. For each image grid, the left side is the decoupler-output AD pathologic probability map, the upper right side is the original Aβ/tau PET image, and the lower right side is the image after AD component removal by the decoupler.
Consortium launches 5-year plan to improve theranostics outcomes
By Will Morton
The project aims to pave the way for personalized radiopharmaceutical therapy.
April 6, 2026
Isotopes1
SpectronRx raises $85M to expand radiopharmaceutical production
By AuntMinnie.com staff writers
The funding will support infrastructure investment at the company's Grissom Aeroplex campus in Indiana.
April 2, 2026
Cash
Catalyst MedTech expands brain PET deployment program
By AuntMinnie.com staff writers
The program integrates the CareMiBrain dedicated brain PET system with quantification tools, clinical workflow support, and service and maintenance.
April 1, 2026
Brain Pet
Cardinal Health expands Ac-225 production
By AuntMinnie.com staff writers
Since launching routine Ac-225 production at scale in late 2024, the company said it has quadrupled its weekly output.
April 1, 2026
Isotopes1
PET/CT metric improves outcome predictions in Pluvicto patients
By Will Morton
The inclusion of total tumor volume (TTV) produces prediction models with better discriminatory ability.
March 31, 2026
PSMA-PET images. (A) Representative examples illustrate the variability in the total tumor volume (TTV) among patients stratified by the number of metastatic lesions. (B) Case examples demonstrate TTV segmentation across a range of TTV values. Notably, as the tumor volume increased, a visible decrease in radiopharmaceutical uptake by normal organs is observed, particularly in the salivary glands, kidneys, and liver (denoted by brackets), a phenomenon known as the “sink effect.” SUV = standardized uptake value.
New recommendations issued on tau PET imaging
By AuntMinnie.com staff writers
Standardized imaging procedures are essential to facilitate the integration of tau PET into clinical workflows.
March 31, 2026
Examples of tau PET patterns in atypical AD and 4R tauopathies. Three axial slices upon MRI or MRI template show radiotracer distribution in exemplary cases of atypical AD and progressive supranuclear palsy (PSP).
BAMF Health announces fundraising for theranostics access
By AuntMinnie.com staff writers
FAMB board begins fundraising to cover theranostics care that falls outside of insurance coverage or research protocols.
March 31, 2026
Business Handshake Intelligence Sm
Radiopharmaceutical Therapy Tracker
With so many targeted diagnostic and therapeutic radiopharmaceuticals in development for cancer care, AuntMinnie's new pipeline update tool can help keep track.
March 30, 2026
Rt Tracker
PET reveals disease activity in autoimmune encephalitis
By Will Morton
PET revealed brain region-specific astrogliosis corresponding to clinical manifestations and disease severity.
March 26, 2026
(A) Overview of study participants with different clinical phenotypes depicted in distinct colors: Limbic encephalitis (LE)/temporal lobe epilepsy (TLE): Blue; cerebellar ataxia (CA): Green; stiff person syndrome (SPS): Red, including overlapping clinical features with an overview of the analyzed parameter; generated in Biorender. (B) F-18 F-DED uptake, as visualized by SUVr with global mean scaling, is shown for three representative patients with GAD65-AIE: Patient #6 with LE/TLE, showing mesiotemporal F-18 F-DED uptake; patient #16 with overlapping clinical features of CA, SPS, and LE, showing both mesiotemporal and cerebellar F-18 F-DED uptake; and patient #17 with isolated SPS showing no increased F-18 F-DED uptake. Additionally, the average F-18 F-DED uptake of eight controls is shown on the right.
U.S. DOE, MURR establish domestic Gd-153 supply
By AuntMinnie.com staff writers
The organizations are now positioned as the sole domestic supplier of the radioisotope and one of only two suppliers globally.
March 25, 2026
Isotope Atom Space 400
Page 1 of 623
Next Page